A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia.

@article{Fenaux1991ART,
  title={A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia.},
  author={Pierre Fenaux and G{\'e}rard Tertian and Sylvie Castaigne and Herv{\'e} Tilly and Guy G Leverger and Harold P. Guy and Dominique Bordessoule and R. Leblay and E le Gall and Philippe Colombat},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1991},
  volume={9 9},
  pages={1556-61}
}
Thirty-nine patients with untreated acute promyelocytic leukemia (APL) were randomly allocated to receive rubidazone (zorubicin) 200 mg/m2/d, days 1 to 4 plus cytarabine (Ara C) 200 mg/m2/d, days 1 to 7 (arm A, 21 patients), or amsacrine (Amsa) 150 mg/m2/d, days 1 to 4 plus Ara C 200 mg/m2/d, days 1 to 7 (arm B, 18 patients). Prophylaxis of disseminated… CONTINUE READING